RU EN

Mordovin V.F.

Doctor of Medical Sciences, Professor

Department of Hypertension

H-index: RSCI 12, Scopus 5, Web of Science 5

Articles

  1. Pekarskiy S.E., Baev A.E., Falkovskaya A.Yu., Lichikaki V.A., Sitkova E.S., Zubanova I.V., Manukyan M.A., Tarasov M.G., Mordovin V.F., Popov S.V. Durable strong efficacy and favorable long-term renal safety of the anatomically optimized distal renal denervation according to the 3 year follow-up extension of the double-blind randomized controlled trial. Heliyon 2022;8(1):1-6.
  2. Bhatt D.L., Steg P.G., Miller M., Brinton E.A., Jacobson T.A., Ketchum S.B., Doyle Jr R.T., Juliano R.A., Jiao L., Granowitz C., Tardif J.C., Ballantyne C.M., Mordovin Viktor, Falkovskaya Alla, Ripp Tatiana, Triss Sergei, Pekarskiy Stanislav, Sitkova Ekaterina Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine 2019;380(1):11-22.
  3. Pekarskiy S.E., Baev A.E., Mordovin V.F., Semke G.V., Ripp T.M., Falkovskaya A.U., Lichikaki V., Sitkova E.S., Zubanova I.V., Popov S. Denervation of the distal renal arterial branches versus conventional main renal artery treatment: a randomised controlled trial for treatment of resistant hypertension. Journal of Hypertension 2017;35(2):369-375.
  4. Ripp T.M., Mordovin V.F., Pekarskiy S.E., Ryabova T.R., Zlobina M.V., Baev A.E., Anfinogenova Y., Popov S.V. Predictors of renal denervation efficacy in the treatment of resistant hypertension. Current Hypertension Reports 2015;17(12):1-7.